Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHND9041 vs Afatinib in First-line EGFR-mutated NSCLC
NCT06759857Phase 3Enrolling by invitation
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of FHND-9041 in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.. Started Aug 2021; status: enrolling by invitation.
02
Drugs
FHND-9041
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06759857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759857.